L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy
Hiroshi Asano(Hokkaido University), Hidemichi Watari(Hokkaido University of Science), Noriko Kobayashi(Tokyo Medical University), Takashi Mitamura(Sapporo University), Kanako C. Hatanaka(Hokkaido University Hospital), Ayako Nozaki(Hokkaido University), Yosuke Konno(Hokkaido University of Science), Yoshihiro Matsuno(Hokkaido University Hospital), Kei Ihira(Hokkaido University), Yutaka Hatanaka(Hokkaido University), Tatsuya Kato(Hokkaido University), Ryosuke Matsuoka(International University of Health and Welfare), Akira Oku(Hokkaido University), Peixin Dong(Hokkaido University of Science)
Cited by 27
Related Papers
Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis
|Oncogene|2012|305
Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study
|Journal of Thoracic Oncology|2016|273
Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells
|Cancer Research|2016|178
Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes
|Journal of Experimental & Clinical Cancer Research|2019|164